LifeMD Announces Annual Meeting Results

LifeMD , Inc. (NASDAQ:LFMD), a provider of telehealth services and products with a market capitalization of $613 million, conducted its annual meeting of stockholders on June 13, 2025, where it successfully passed all proposed resolutions. The meeting saw the re-election of seven directors and the ratification of the company’s independent auditor for the upcoming fiscal year. According to InvestingPro data, the company has shown impressive growth with revenue increasing 43% year-over-year, while maintaining industry-leading gross profit margins of 88%.

At the annual meeting, a quorum was present, with a majority of the issued and outstanding shares represented either in person or by proxy. The meeting comes at a time when LifeMD’s stock is trading near its 52-week high of $13.25, reflecting strong investor confidence. The stockholders voted on two key proposals:

Proposal 1 involved the election of seven directors to serve on the company’s board until the next annual meeting. All seven nominees were re-elected, with votes for each director ranging from 16,814,158 to 21,567,314. Votes withheld varied from 487,174 to 5,240,330, and there were 9,704,772 broker non-votes for each director.

Proposal 2 was the ratification of the appointment of CBIZ (NYSE:CBZ) CPAs, P.C. as LifeMD’s independent registered public accounting firm for the fiscal year ending December 31, 2025. This proposal received overwhelming support, with 31,541,717 votes for, 38,368 against, and 179,175 abstentions.

The approval of both proposals signifies shareholder confidence in the current board’s direction and the company’s accounting practices. The re-elected board members include Justin Schreiber, Dr. Joseph V. DiTrolio, M.D., Roberto Simon, John R. Strawn, Jr., Dr. Joan LaRovere, M.D., William Febbo, and Dr. Calum MacRae, M.D., Ph.D.

This summary of LifeMD’s annual meeting outcomes is based on the company’s recent 8-K filing with the SEC. While analysts tracked by InvestingPro predict profitability this year, there are 13 additional key insights available to subscribers, along with comprehensive financial analysis and Fair Value estimates in the Pro Research Report, helping investors make more informed decisions about this rapidly growing telehealth company.

In other recent news, LifeMD reported impressive first-quarter 2025 financial results, with total revenue reaching $65.7 million, a 49% increase year-over-year, surpassing forecasts of $62.37 million. The company achieved a positive earnings per share (EPS) of $0.01, exceeding the anticipated -$0.0583. Following these results, LifeMD raised its full-year 2025 revenue guidance to a range of $268-$275 million and adjusted its EBITDA forecast to $31-$33 million. Analysts at Cantor Fitzgerald reiterated their Overweight rating on LifeMD with a price target of $15.00, citing improved customer retention as a key factor in the earnings beat. BTIG analysts also maintained a Buy rating with a $12.00 price target, highlighting the significant role of healthcare product revenue, particularly from obesity health-related products, in the revenue increase. Additionally, LifeMD launched a new weight management bundle, including Wegovy® and a virtual weight loss program, priced at $299 for the first month. This initiative is part of a collaboration with Novo Nordisk (NYSE:NVO) to enhance access to weight-loss solutions. The company’s strategic expansions into new healthcare verticals, such as women’s health and behavioral health, were also noted as contributing factors to its robust performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.